University of Leiden


The research of the Division of Analytical Biosciences at the Leiden/Amsterdam Center for Drug Research is directed to develop innovative analytical tools for metabolomics-driven systems biology in personalized health strategies.

University of Leiden uses a range of global platforms using LC-high resolution MS detection (TOF, QTOF and Orbitrap-MS) in addition to targeted methods using mostly LC-QQQ MS/MS to cover lower concentrations or metabolites requiring special sample preparation/ stabilization. University of Leiden is leading the Netherlands Metabolomics Centre (NMC) which directs significant efforts to developing better metabolomics platforms for quantitative data and identification of metabolites. Additional newly developed platforms will be available soon. Using different RPLC-QQQ MS/MS protocols, 20 one-carbon carriers, 50 steroids and 15 catecholamines will be targeted, in addition to 90 amines which will require derivatization. By extending the existing HILIC-QTOF MS/MS platform, 250 acids, nucleotides, sugars and related compounds will be quantified. These platforms will be complemented by screening 130 identified anionic and cationic compounds using CE-QTOF-MS. Altogether, the University of Leiden will largely extend its metabolomics platforms to up to 1,500 identified metabolites in blood and urine. New approaches using LCxLC and new LC-MS interfaces using microfluidics/nanofludics will be developed and integrated into the metabolomics platforms to improve the coverage and robustness of metabolomics data, and miniaturized analytical systems will be developed to allow the metabolomics analysis of ultrasmall samples as biopsies and even ultimately individual cells.

U Leiden uses HILIC-MS/MS protocols for profiling over 100 biogenic amines.

The Analytical Biosciences group at Leiden University:

The Netherlands Metabolomics Centre:


-A A +A